OTC Markets OTCPK - Delayed Quote USD

Bioqual, Inc. (BIOQ)

45.00
0.00
(0.00%)
As of May 19 at 4:00:00 PM EDT. Market Open.
Loading Chart for BIOQ
  • Previous Close 45.00
  • Open 45.00
  • Bid 44.25 x --
  • Ask 45.80 x 40000
  • Day's Range 45.00 - 45.00
  • 52 Week Range 45.00 - 72.50
  • Volume 100
  • Avg. Volume 104
  • Market Cap (intraday) 40.249M
  • Beta (5Y Monthly) 0.02
  • PE Ratio (TTM) 15.85
  • EPS (TTM) 2.84
  • Earnings Date Apr 11, 2025
  • Forward Dividend & Yield 0.50 (1.11%)
  • Ex-Dividend Date Oct 7, 2024
  • 1y Target Est --

Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.

www.bioqual.com

--

Full Time Employees

May 31

Fiscal Year Ends

Recent News: BIOQ

View More

Performance Overview: BIOQ

Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BIOQ
31.92%
S&P 500 (^GSPC)
1.10%

1-Year Return

BIOQ
37.47%
S&P 500 (^GSPC)
12.02%

3-Year Return

BIOQ
33.84%
S&P 500 (^GSPC)
52.42%

5-Year Return

BIOQ
33.64%
S&P 500 (^GSPC)
100.10%

Compare To: BIOQ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIOQ

View More

Valuation Measures

Annual
As of 5/19/2025
  • Market Cap

    40.25M

  • Enterprise Value

    51.52M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.34%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    49M

  • Net Income Avi to Common (ttm)

    -2.13M

  • Diluted EPS (ttm)

    2.84

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.46M

  • Total Debt/Equity (mrq)

    51.42%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: BIOQ

View More

Company Insights: BIOQ

Research Reports: BIOQ

View More

People Also Watch